

Specialty Pharmacy Program

Zytiga™ (abiraterone)

DESCRIPTION

Zytiga, in combination with prednisone, is indicated for the treatment of patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel. Zytiga is an oral androgen biosynthesis inhibitor that inhibits the CYP17 enzyme. This enzyme is expressed in testicular, adrenal, and prostatic tumor tissues and is required for androgen biosynthesis.

APPROVAL DURATION

Approval duration: 1 year

APPROVAL CRITERIA

Zytiga will be approved if the patient meets the following criteria:

- I. Patient has a diagnosis of prostate cancer **AND**
- II. Prostate cancer is metastatic and castration-resistant **AND**
- III. Patient received prior chemotherapy containing docetaxel **AND**
- IV. Zytiga is used in combination with prednisone.